Publication | Closed Access
Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Weekly Paclitaxel in Patients with Solid Tumors
21
Citations
21
References
2007
Year
The recommended dose of lonafarnib for phase II trials is 125 mg orally twice daily when combined with weekly paclitaxel 80 mg/m(2). The dose-limiting toxicity was neutropenia.
| Year | Citations | |
|---|---|---|
Page 1
Page 1